Cancer Immunotherapy News and Research

RSS

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.

3 Nov 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

New research raises hope for novel cancer immunotherapy

New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

16 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.

25 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.

8 Sep 2015

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

28 Aug 2015

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

Immatics Biotechnologies GmbH and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.

26 Aug 2015

New research could potentially yield novel platform for cancer vaccines

New research led by Wyss Core Faculty member David Mooney, Ph.D., in collaboration with researchers at the Dana-Farber Cancer Institute could potentially yield a new platform for cancer vaccines. Leveraging a biologically inspired sponge-like gel called "cryogel" as an injectable biomaterial, the vaccine delivers patient-specific tumor cells together with immune-stimulating biomolecules to enhance the body's attack againstcancer.

26 Aug 2015

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.

26 Aug 2015

Early exposure to inflammatory cytokines can paralyze CD4 T cells

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help orchestrate the body's response to pathogens and other invaders.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Cancer Immunotherapy News and Research

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

New research raises hope for novel cancer immunotherapy

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Leading cancer researchers address eight 'big questions'

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

Aspirin may help boost effectiveness of cancer treatment

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptive immune system plays active role in guiding development of mammary glands

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

New research could potentially yield novel platform for cancer vaccines

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

Early exposure to inflammatory cytokines can paralyze CD4 T cells

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News